<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634409</url>
  </required_header>
  <id_info>
    <org_study_id>18160</org_study_id>
    <secondary_id>J2X-MC-PYAH</secondary_id>
    <nct_id>NCT04634409</nct_id>
  </id_info>
  <brief_title>A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness</brief_title>
  <acronym>BLAZE-4</acronym>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbCellera Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vir Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure how well monoclonal antibodies work, either alone or&#xD;
      in combination, against the virus that causes COVID-19. Study drug(s) will be given to&#xD;
      participants with early symptoms of COVID-19. Samples will be taken from the back of the nose&#xD;
      to determine how much virus is in the body at various times during the study. Participation&#xD;
      could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the&#xD;
      remainder of assessments performed in the home, local clinic, or by phone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2020</start_date>
  <completion_date type="Actual">October 18, 2021</completion_date>
  <primary_completion_date type="Actual">July 27, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Includes open label arms</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Greater Than 5.27</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Relevance Sequence Imputation (RSI). RSI is defined as follows: If Day 7 SARS-CoV-2 viral load is missing, then Day 7 will be imputed using data from the first available for Day 5, Day 3, Day 11, or Day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment 7-8, Amendments (C-e): Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment 12 -13, Amendment (f) High Risk Participants: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 14, Amendment (f) High Risk Participants Updated CDC Criteria: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addendum (2): Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</measure>
    <time_frame>Day 7</time_frame>
    <description>Missing data is estimated using Relevance Sequence Imputation (RSI). RSI is defined as follows: If Day 7 SARS-CoV-2 viral load is missing, then Day 7 will be imputed using data from the first available for Day 5, Day 3, Day 11, or Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addendum (4), Arm A - Intravenous: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addendum (4) Arm B - Subcutaneous: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</measure>
    <time_frame>Day 7</time_frame>
    <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death from any Cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 7-8, Amendment (C-E): Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death from Any Cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 14 Amendment (f) High Risk Participants, Updated CDC Criteria: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 1-6 and Unintentional Dosing Arms: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Least squares mean (LSM) change from baseline was calculated using a mixed model repeating measures (MMRM) that included log base 10 transformed baseline as a covariate, treatment, day, treatment-by-day interaction as fixed effects. Viral load is reported as normalized viral and is unitless.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 7-8 Amendments (C-e): Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>LSM change from baseline was calculated using a MMRM that included log base 10 transformed baseline as a covariate, treatment, day, treatment-by-day interaction as fixed effects. Viral load is reported as normalized viral and is unitless.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 9-11 Amendment (f), Low Risk Participants: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>LSM change from baseline was calculated using a MMRM that included log base 10 transformed baseline as a covariate, treatment, day, treatment-by-day interaction as fixed effects. Viral load is reported as normalized viral and is unitless.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 12 -13 Amendment (f), High Risk Participants: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 14, Amendment (f) High Risk Participants Updated CDC Criteria: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addendum 4, IV: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addendum 4, SC: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addendum (2): Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Demonstrating Symptom Resolution</measure>
    <time_frame>Day 7</time_frame>
    <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as all symptoms (excluding loss of appetite, taste, and smell) on the symptom questionnaire scored as absent (score of 0). Missing data was imputed using a non-responder imputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 7-8 Amendments (C-e): Percentage of Participants Demonstrating Symptom Resolution</measure>
    <time_frame>Day 7</time_frame>
    <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as all symptoms (excluding loss of appetite, taste, and smell) on the symptom questionnaire scored as absent (score of 0). Missing data was imputed using a non-responder imputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Demonstrating Symptom Resolution</measure>
    <time_frame>Day 7</time_frame>
    <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as a score of 0 for shortness of breath, feeling feverish, body aches and pains, sore throat, chills, and headache, and a score of 0 or 1 for cough and fatigue on the symptom questionnaire. Missing data was imputed using a non-responder imputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Demonstrating Symptom Resolution</measure>
    <time_frame>Day 7</time_frame>
    <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as a score of 0 for shortness of breath, feeling feverish, body aches and pains, sore throat, chills, and headache, and a score of 0 or 1 for cough and fatigue on the symptom questionnaire. Missing data was imputed using a non-responder imputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 14, Amendment (g) High Risk Participants Updated CDC Criteria Amendment (g): Percentage of Participants Demonstrating Symptom Resolution</measure>
    <time_frame>Day 7</time_frame>
    <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as a score of 0 for shortness of breath, feeling feverish, body aches and pains, sore throat, chills, and headache, and a score of 0 or 1 for cough and fatigue on the symptom questionnaire. Missing data was imputed using a non-responder imputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Demonstrating Symptom Improvement</measure>
    <time_frame>Day 7</time_frame>
    <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 7-8 Amendments (C-E): Percentage of Participants Demonstrating Symptom Improvement</measure>
    <time_frame>Day 7</time_frame>
    <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Demonstrating Symptom Improvement</measure>
    <time_frame>Day 7</time_frame>
    <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Demonstrating Symptom Improvement</measure>
    <time_frame>Day 7</time_frame>
    <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 14 Amendment (g): Percentage of Participants Demonstrating Symptom Improvement</measure>
    <time_frame>Day 7</time_frame>
    <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 7-8 Amendments (C-E): Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment 14 Amendment (g): Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Mean Concentration of Bamlanivimab</measure>
    <time_frame>Day 29</time_frame>
    <description>PK: Mean Concentration of Bamlanivimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Mean Concentration of Etesevimab</measure>
    <time_frame>Day 29</time_frame>
    <description>Pharmacokinetics (PK): Mean Concentration of Etesevimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Mean Concentration of Bebtelovimab</measure>
    <time_frame>Day 29</time_frame>
    <description>Pharmacokinetics (PK): Mean Concentration of Bebtelovimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Mean Concentration of VIR-7831</measure>
    <time_frame>Day 29</time_frame>
    <description>PK: Mean Concentration of VIR-7831</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1755</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Placebo (Pbo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment 1: Pbo administered intravenously (IV).&#xD;
Treatment 8: Pbo For 700 mg Bamlanivimab (BAM) + 500 mg VIR-7831 (Amendment (C-e)) administered IV.&#xD;
Treatment 11: Pbo For 175 mg Bebtelovimab (BEB) &amp; 700 mg BAM +1400 mg Etesevimab ( ETE) +175 mg BEB (Low Risk Participants) administered IV.&#xD;
Pooled Placebo (Addendum 4, IV) administered IV.&#xD;
Pooled Placebo (Addendum 4, SC) administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAM + ETE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 2: 175 mg BAM +350 mg ETE administered IV.&#xD;
Treatment 3: 700 mg BAM +1400 mg ETE administered IV.&#xD;
Treatment 4: 2800 mg BAM +2800 mg ETE administered IV.&#xD;
Treatment 6: 350 mg BAM +700 mg ETE administered IV.&#xD;
Unintentional Dosing: 700 mg BAM +700 mg ETE administered IV.&#xD;
700 mg BAM + 1400 mg ETE 30-min (Addendum (2)) administered IV.&#xD;
700 mg BAM + 1400 mg ETE 15-min (Addendum (2)) administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 5: 700 mg BAM administered IV.&#xD;
700 mg BAM 15-min (Addendum (2)) administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAM + VIR-7831</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e)) administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants) administered IV.&#xD;
Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants) administered IV.&#xD;
70 mg BEB 140 mg/Min (Addendum 4, IV) administered IV.&#xD;
175 mg BEB 140 mg/Min (Addendum 4, IV) administered IV.&#xD;
175 mg BEB 350 mg/Min (Addendum 4, IV) administered IV.&#xD;
1750 mg BEB 350 mg/Min (Addendum 4, IV) administered IV.&#xD;
280 mg BEB (Addendum 4, SC) administered SC.&#xD;
560 mg BEB (Addendum 4, SC) administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAM+ ETE + BEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants) administered IV.&#xD;
Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants) administered IV.&#xD;
Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB(Amendment (g), High Risk, Updated Centers for Disease Control and Prevention (CDC) Criteria) administered IV.&#xD;
175/700/1400 mg BAM + ETE + BEB 350 mg/Min (Addendum 4, IV) administered IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bamlanivimab</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>BAM</arm_group_label>
    <arm_group_label>BAM + ETE</arm_group_label>
    <arm_group_label>BAM + VIR-7831</arm_group_label>
    <arm_group_label>BAM+ ETE + BEB</arm_group_label>
    <other_name>LY-CoV555</other_name>
    <other_name>LY3819253</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etesevimab</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>BAM + ETE</arm_group_label>
    <arm_group_label>BAM+ ETE + BEB</arm_group_label>
    <other_name>LY-CoV016</other_name>
    <other_name>LY3832479</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>Placebo (Pbo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIR-7831</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>BAM + VIR-7831</arm_group_label>
    <other_name>GSK4182136</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bebtelovimab</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>BAM+ ETE + BEB</arm_group_label>
    <arm_group_label>BEB</arm_group_label>
    <other_name>LY-CoV1404, LY3853113</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For low-risk participant arms 9-11 only: Are greater than or equal to (≥)18 and less&#xD;
             than (&lt;)65 years of age at the time of randomization and do not have the risk factors&#xD;
             defined in the bullet point directly below&#xD;
&#xD;
          -  For high-risk participant arms 12 and 13 only:&#xD;
&#xD;
             -- Are ≥18 years of age and satisfy at least one of the following risk factors at the&#xD;
             time of screening&#xD;
&#xD;
               -  Are ≥65 years of age&#xD;
&#xD;
               -  Have a body mass index (BMI) ≥ 35&#xD;
&#xD;
               -  Have chronic kidney disease&#xD;
&#xD;
               -  Have type 1 or type 2 diabetes&#xD;
&#xD;
               -  Have immunosuppressive disease&#xD;
&#xD;
               -  Are currently receiving immunosuppressive treatment, or&#xD;
&#xD;
               -  Are ≥55 years of age AND have&#xD;
&#xD;
                    -  cardiovascular disease, OR&#xD;
&#xD;
                    -  hypertension, OR&#xD;
&#xD;
                    -  chronic obstructive pulmonary disease or other chronic respiratory disease&#xD;
&#xD;
          -  For high-risk participant arms 12 and 13 only:&#xD;
&#xD;
               -  Are 12-17 years of age (inclusive) AND satisfy at least one of the following risk&#xD;
                  factors at the time of screening&#xD;
&#xD;
                    -  Have a BMI ≥85th percentile for their age and gender based on CDC growth&#xD;
                       charts, https://www.cdc.gov/growthcharts/clinical_charts.htm&#xD;
&#xD;
                    -  Have sickle cell disease&#xD;
&#xD;
                    -  Have congenital or acquired heart disease&#xD;
&#xD;
                    -  Have neurodevelopmental disorders, for example, cerebral palsy&#xD;
&#xD;
                    -  Have a medical-related technological dependence, for example, tracheostomy,&#xD;
                       gastrostomy, or positive pressure ventilation (not related to COVID-19)&#xD;
&#xD;
                    -  Have asthma or reactive airway or other chronic respiratory disease that&#xD;
                       requires daily medication for control&#xD;
&#xD;
                    -  Have type 1 or type 2 diabetes&#xD;
&#xD;
                    -  Have chronic kidney disease&#xD;
&#xD;
                    -  Have immunosuppressive disease, or&#xD;
&#xD;
                    -  Are currently receiving immunosuppressive treatment.&#xD;
&#xD;
        For high-risk participants arm 14 only:&#xD;
&#xD;
          -  Are ≥12 years of age and satisfy at least one of the following risk factors at the&#xD;
             time of screening Are ≥65 years of age&#xD;
&#xD;
          -  Are adults (≥18 years of age) with BMI &gt;25 kg/m2 , or if age 12-17, have BMI ≥85th&#xD;
             percentile for their age and gender based on CDC growth charts&#xD;
&#xD;
          -  Have chronic kidney disease&#xD;
&#xD;
          -  Have type 1 or type 2 diabetes&#xD;
&#xD;
          -  Have immunosuppressive disease&#xD;
&#xD;
          -  Are currently receiving immunosuppressive treatment&#xD;
&#xD;
          -  Have cardiovascular disease (including congenital heart disease) or hypertension&#xD;
&#xD;
          -  Have chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma&#xD;
             [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary&#xD;
             hypertension)&#xD;
&#xD;
          -  Have sickle cell disease&#xD;
&#xD;
          -  Have neurodevelopmental disorder (for example, cerebral palsy) or other conditions&#xD;
             that confer medical complexity (for example, genetic or metabolic syndromes and severe&#xD;
             congenital anomalies)&#xD;
&#xD;
          -  Have a medical-related technological dependence (for example, tracheostomy,&#xD;
             gastrostomy, or positive pressure ventilation [not related to COVID-19]&#xD;
&#xD;
          -  Are currently not hospitalized&#xD;
&#xD;
          -  Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat,&#xD;
             malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with&#xD;
             exertion, nasal congestion or runny nose, new loss of smell, chills&#xD;
&#xD;
          -  Must have sample taken for test confirming viral infection no more than 3 days prior&#xD;
             to starting the drug infusion&#xD;
&#xD;
          -  Are men or non-pregnant women who agree to contraceptive requirements&#xD;
&#xD;
          -  Understand and agree to comply with planned study procedures&#xD;
&#xD;
          -  Agree to the collection of nasopharyngeal swabs and venous blood&#xD;
&#xD;
          -  The participant or legally authorized representative give signed informed consent&#xD;
             and/or assent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For low-risk participants only: BMI ≥35&#xD;
&#xD;
          -  Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air at&#xD;
             sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of&#xD;
             mercury) to fractional inspired oxygen (FiO2) &lt;300, respiratory rate ≥30 per minute,&#xD;
             heart rate ≥125 per minute&#xD;
&#xD;
          -  Require mechanical ventilation or anticipated impending need for mechanical&#xD;
             ventilation&#xD;
&#xD;
          -  Have known allergies to any of the components used in the formulation of the&#xD;
             interventions&#xD;
&#xD;
          -  Have hemodynamic instability requiring use of pressors within 24 hours of&#xD;
             randomization&#xD;
&#xD;
          -  Suspected or proven serious, active bacterial, fungal, viral, or other infection&#xD;
             (besides COVID-19) that in the opinion of the investigator could constitute a risk&#xD;
             when taking intervention&#xD;
&#xD;
          -  Have any co-morbidity requiring surgery within &lt;7 days, or that is considered&#xD;
             life-threatening within 29 days&#xD;
&#xD;
          -  Have any serious concomitant systemic disease, condition or disorder that, in the&#xD;
             opinion of the investigator, should preclude participation in this study&#xD;
&#xD;
          -  Have a history of a positive severe acute respiratory syndrome coronavirus 2&#xD;
             (SARS-CoV-2) test prior to the one serving as eligibility for this study&#xD;
&#xD;
          -  Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30&#xD;
             days before dosing&#xD;
&#xD;
          -  Have received treatment with a SARS-CoV-2 specific monoclonal antibody&#xD;
&#xD;
          -  Have a history of convalescent COVID-19 plasma treatment&#xD;
&#xD;
          -  For low-risk arms only: have received a SARS-CoV-2 vaccine or have participated in a&#xD;
             previous SARS-CoV-2 vaccine study and are currently blinded to treatment allotment&#xD;
&#xD;
          -  Have participated, within the last 30 days, in a clinical study involving an&#xD;
             investigational intervention. If the previous investigational intervention has a long&#xD;
             half-life, 5 half-lives or 30 days, whichever is longer, should have passed&#xD;
&#xD;
          -  Are concurrently enrolled in any other type of medical research judged not to be&#xD;
             scientifically or medically compatible with this study&#xD;
&#xD;
          -  Are pregnant or breast feeding&#xD;
&#xD;
          -  Are investigator site personnel directly affiliated with this study&#xD;
&#xD;
          -  Have body weight &lt;40 kilograms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Liver Health</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perseverance Research Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI of Arizona, LLC</name>
      <address>
        <city>Sun City West</city>
        <state>Arizona</state>
        <zip>85375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiel Family and Sports Medicine PC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Liver Health</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLR Business Group, Inc. dba Arkansas Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Applied Rsch Ctr - Arkansas Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smart Cures Clin Research</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VCT-Covina</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neighborhood Healthcare</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chemidox Clinical Trials</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ark Clinical Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Clinical Trials LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048-5615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Valley Research, LLC</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Institute For Medical Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolverine Clinical Trials, LLC</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joe Heritage HC-Santa Rosa</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazur, Statner, Dutta, Nathan</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bay Clinical Research Institute</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infect Disease Doctors Med Grp</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allianz Research Institute</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Innovative Treatments LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Univ Sch of Med</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Healthcare LLC</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital Inc.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I R &amp; Health Center, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encore Medical Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elixia CRC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Medical Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panax Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Trials, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute at Baptist Health, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bio-Medical Research, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33184</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site Partners, LLC d/b/a CSP Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Testing Matters Lab</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advent Health Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Research Inst</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encore Medical Research - Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site Partners, LLC DBA CSP Orlando</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Research Inst</name>
      <address>
        <city>Buford</city>
        <state>Georgia</state>
        <zip>30519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Rch Sol - College Pk</name>
      <address>
        <city>College Park</city>
        <state>Georgia</state>
        <zip>30349</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IACT Health - VHC</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Georgia Infectious Disease</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rophe Adult and Pediatric Medicine</name>
      <address>
        <city>Union City</city>
        <state>Georgia</state>
        <zip>30291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Clinical Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Health Hammond</name>
      <address>
        <city>Dyer</city>
        <state>Indiana</state>
        <zip>46311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualmedica Research Evansville</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Vincent - Indy</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualmedica Research, LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research,LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial Health Urgent Care Center - Moss Bluff</name>
      <address>
        <city>Moss Bluff</city>
        <state>Louisiana</state>
        <zip>70611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nola Research Works, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U of MA Mem Med Ctr</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Research Group, Inc.</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revive Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revival Research Institute</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sky Clinical Prime and Health Wellness Clinic</name>
      <address>
        <city>Fayette</city>
        <state>Mississippi</state>
        <zip>39069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olive Branch Family Medical Center</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sky Clin Resch - Quinn HC</name>
      <address>
        <city>Ridgeland</city>
        <state>Mississippi</state>
        <zip>39157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bio-Kinetic Clinical Applications, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excel Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Medical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SVG Clinical</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prime Global Research, LLC</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onsite Clinical Solutions, LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Biomed Research</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carteret Medical Group</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Medical Primary Care</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hometown UC and Rch- Cincy</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urgent Care Specialists, LLC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remington-Davis, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urgent Care Specialists, LLC</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>META Medical Research Institute</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Tulsa OK</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jefferson Hosp for Neurosci</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITALINK - Anderson</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Medical Research - Clinton</name>
      <address>
        <city>Clinton</city>
        <state>South Carolina</state>
        <zip>29325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITALINK - Gaffney</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Medical Research - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITALINK - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITALINK - Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITALINK - Union</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Diab &amp; Endo Consult</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Phase Research and Development</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gadolin Research, LLC</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conroe Willis Medical Research</name>
      <address>
        <city>Conroe</city>
        <state>Texas</state>
        <zip>77304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinical Research</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B S &amp; W Med Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Clinical Trials, LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Ins</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Next Level Urgent Care</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management, LLC.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1960 Family Practice, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>B S &amp; W Med Center</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zion Urgent Care Clinic</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioPharma Family Practice Center McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BRCR Medical Center, Inc</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Hills Medical Research</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <zip>76180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Infectious Diseases Associates</name>
      <address>
        <city>Pasadena</city>
        <state>Texas</state>
        <zip>77505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epic Medical Research</name>
      <address>
        <city>Red Oak</city>
        <state>Texas</state>
        <zip>75154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor - Round Rock</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consano Clinical Research, LLC</name>
      <address>
        <city>Shavano Park</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APD Clinical Research</name>
      <address>
        <city>Splendora</city>
        <state>Texas</state>
        <zip>77372</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossroads Clin Rch-Victoria</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLS Research Ctr, PLLC</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CARE ID</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evergreen Health Research</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Sagrado Corazón</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <state>AR</state>
        <zip>C1039AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Zabala</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <state>AR</state>
        <zip>C1426AAM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio de la Trinidad Mitre</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1039AAO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Privada Independencia</name>
      <address>
        <city>Munro</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Go Centro Medico San Nicolás</name>
      <address>
        <city>San Nicolás</city>
        <state>Buenos Aires</state>
        <zip>B2900DPA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Zarate</name>
      <address>
        <city>Zárate</city>
        <state>Buenos Aires</state>
        <zip>2800</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Médico Rio Cuarto</name>
      <address>
        <city>Rio Cuarto</city>
        <state>Cordoba</state>
        <zip>X5800AEV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Central S.A.</name>
      <address>
        <city>Villa Regina</city>
        <state>Rio Negro</state>
        <zip>R8336</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clínicas - Clínica Viedma</name>
      <address>
        <city>Viedma</city>
        <state>RN</state>
        <zip>8500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INECO Neurociencias Oroño</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Roque</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research, LLC</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorado Medical Complex Inc</name>
      <address>
        <city>Dorado</city>
        <zip>00646</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group, PSC - Hato Rey Site</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/3GPxb8Mwm9PjgI7IrKcsTB</url>
    <description>A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness</description>
  </link>
  <verification_date>June 2022</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <results_first_submitted>June 7, 2022</results_first_submitted>
  <results_first_submitted_qc>June 7, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2022</results_first_posted>
  <last_update_submitted>June 7, 2022</last_update_submitted>
  <last_update_submitted_qc>June 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bamlanivimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Protocol: J2X-MC-PYAH</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 18, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04634409/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Protocol Addendum 2: J2X-MC-PYAH</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04634409/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Protocol Addendum 4: J2X-MC-PYAH</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04634409/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 4, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT04634409/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment 1: Pbo</title>
          <description>Participants received placebo (Pbo) administered intravenously (IV).</description>
        </group>
        <group group_id="P2">
          <title>Treatment 2: 175 mg BAM +350 mg ETE</title>
          <description>Participants received 175 milligrams (mg) bamlanivimab (BAM) +350 mg etesevimab (ETE) administered IV.</description>
        </group>
        <group group_id="P3">
          <title>Treatment 3: 700 mg BAM +1400 mg ETE</title>
          <description>Participants received 700 mg BAM +1400 mg ETE administered IV.</description>
        </group>
        <group group_id="P4">
          <title>Treatment 4: 2800 mg BAM +2800 mg ETE</title>
          <description>Participants received 2800 mg BAM + 2800 mg ETE administered IV.</description>
        </group>
        <group group_id="P5">
          <title>Treatment 5: 700 mg BAM</title>
          <description>Participants received 700 mg BAM administered IV.</description>
        </group>
        <group group_id="P6">
          <title>Treatment 6: 350 mg BAM +700 mg ETE</title>
          <description>Participants received 350 mg BAM +700 mg ETE administered IV.</description>
        </group>
        <group group_id="P7">
          <title>Unintentional Dosing: 700 mg BAM +700 mg ETE</title>
          <description>Participants received 700 mg BAM +700 mg ETE administered IV.</description>
        </group>
        <group group_id="P8">
          <title>Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
          <description>Participants received 700 mg BAM + 500 mg VIR-7831 administered IV.</description>
        </group>
        <group group_id="P9">
          <title>Treatment 8: Pbo For 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
          <description>Participants received placebo administered IV.</description>
        </group>
        <group group_id="P10">
          <title>Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants)</title>
          <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 175 mg bebtelovimab (BEB) administered IV.</description>
        </group>
        <group group_id="P11">
          <title>Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants)</title>
          <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
        </group>
        <group group_id="P12">
          <title>Treatment 11: Pbo For 175 mg BEB &amp; 700 mg BAM +1400 mg ETE +175 mg BEB (Low Risk Participants)</title>
          <description>Amendment (f) Low Risk Participants:&#xD;
Participants received placebo administered IV.</description>
        </group>
        <group group_id="P13">
          <title>Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants)</title>
          <description>Amendment (f) High Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
        </group>
        <group group_id="P14">
          <title>Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants)</title>
          <description>Amendment (f) High Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
        </group>
        <group group_id="P15">
          <title>Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB(Amendment (g), High Risk,Updated CDC Criteria)</title>
          <description>Amendment (g), High Risk, Updated CDC Criteria):&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV for participants in updated CDC criteria.</description>
        </group>
        <group group_id="P16">
          <title>700 mg BAM 15-min (Addendum (2))</title>
          <description>Participants received 700 mg BAM administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
        </group>
        <group group_id="P17">
          <title>700 mg BAM + 1400 mg ETE 30-min (Addendum (2))</title>
          <description>Participants received 700 mg BAM +1400 mg ETE administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
        </group>
        <group group_id="P18">
          <title>700 mg BAM + 1400 mg ETE 15-min (Addendum (2))</title>
          <description>Participants received 700 mg BAM +1400 mg ETE administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
        </group>
        <group group_id="P19">
          <title>Pooled Placebo (Addendum 4, IV)</title>
          <description>Participants received placebo administered IV.</description>
        </group>
        <group group_id="P20">
          <title>70 mg BEB 140 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 70 mg BEB 140 mg/min IV.</description>
        </group>
        <group group_id="P21">
          <title>175 mg BEB 140 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 175 mg BEB 140 mg/min IV.</description>
        </group>
        <group group_id="P22">
          <title>175 mg BEB 350 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 175 mg BEB 350 mg/min IV.</description>
        </group>
        <group group_id="P23">
          <title>175/700/1400 mg BAM + ETE + BEB 350 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 175 mg BAM + 700 mg ETE + 1400 mg BEB 350 mg/min IV.</description>
        </group>
        <group group_id="P24">
          <title>1750 mg BEB 350 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 1750 mg BEB 350 mg/min IV.</description>
        </group>
        <group group_id="P25">
          <title>Pooled Placebo (Addendum 4, SC)</title>
          <description>Participants received Placebo SC.</description>
        </group>
        <group group_id="P26">
          <title>280 mg BEB (Addendum 4, SC)</title>
          <description>Participants received 280 mg BEB SC.</description>
        </group>
        <group group_id="P27">
          <title>560 mg BEB (Addendum 4, SC)</title>
          <description>Participants received 560 mg BEB SC.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="103"/>
                <participants group_id="P5" count="105"/>
                <participants group_id="P6" count="101"/>
                <participants group_id="P7" count="20">During the study period, 20 participants from the BAM 175-mg + ETE 350-mg arm potentially received 700 mg bamlanivimab + 700 mg etesevimab instead. These 20 participants, who were randomized at 8 different sites were identified through pharmacokinetics analyses.</participants>
                <participants group_id="P8" count="101"/>
                <participants group_id="P9" count="101"/>
                <participants group_id="P10" count="125"/>
                <participants group_id="P11" count="127"/>
                <participants group_id="P12" count="128"/>
                <participants group_id="P13" count="100"/>
                <participants group_id="P14" count="50"/>
                <participants group_id="P15" count="176"/>
                <participants group_id="P16" count="30"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="30"/>
                <participants group_id="P19" count="10"/>
                <participants group_id="P20" count="6"/>
                <participants group_id="P21" count="6"/>
                <participants group_id="P22" count="6"/>
                <participants group_id="P23" count="6"/>
                <participants group_id="P24" count="6"/>
                <participants group_id="P25" count="4"/>
                <participants group_id="P26" count="6"/>
                <participants group_id="P27" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="103"/>
                <participants group_id="P5" count="105"/>
                <participants group_id="P6" count="101"/>
                <participants group_id="P7" count="20"/>
                <participants group_id="P8" count="101"/>
                <participants group_id="P9" count="101"/>
                <participants group_id="P10" count="125"/>
                <participants group_id="P11" count="127"/>
                <participants group_id="P12" count="128"/>
                <participants group_id="P13" count="100"/>
                <participants group_id="P14" count="50"/>
                <participants group_id="P15" count="176"/>
                <participants group_id="P16" count="30"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="30"/>
                <participants group_id="P19" count="10"/>
                <participants group_id="P20" count="6"/>
                <participants group_id="P21" count="6"/>
                <participants group_id="P22" count="6"/>
                <participants group_id="P23" count="6"/>
                <participants group_id="P24" count="6"/>
                <participants group_id="P25" count="4"/>
                <participants group_id="P26" count="6"/>
                <participants group_id="P27" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="150"/>
                <participants group_id="P4" count="96"/>
                <participants group_id="P5" count="102"/>
                <participants group_id="P6" count="99"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="90"/>
                <participants group_id="P9" count="91"/>
                <participants group_id="P10" count="112"/>
                <participants group_id="P11" count="114"/>
                <participants group_id="P12" count="109"/>
                <participants group_id="P13" count="92"/>
                <participants group_id="P14" count="46"/>
                <participants group_id="P15" count="164"/>
                <participants group_id="P16" count="30"/>
                <participants group_id="P17" count="6"/>
                <participants group_id="P18" count="29"/>
                <participants group_id="P19" count="10"/>
                <participants group_id="P20" count="6"/>
                <participants group_id="P21" count="6"/>
                <participants group_id="P22" count="6"/>
                <participants group_id="P23" count="6"/>
                <participants group_id="P24" count="5"/>
                <participants group_id="P25" count="4"/>
                <participants group_id="P26" count="6"/>
                <participants group_id="P27" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="13"/>
                <participants group_id="P11" count="13"/>
                <participants group_id="P12" count="19"/>
                <participants group_id="P13" count="8"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="12"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="1"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="11"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="15"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="7"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="1"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other - As reported by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
                <participants group_id="P24" count="0"/>
                <participants group_id="P25" count="0"/>
                <participants group_id="P26" count="0"/>
                <participants group_id="P27" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment 1: Pbo</title>
          <description>Participants received placebo (Pbo) administered intravenously (IV).</description>
        </group>
        <group group_id="B2">
          <title>Treatment 2: 175 mg BAM +350 mg ETE</title>
          <description>Participants received 175 milligrams (mg) bamlanivimab (BAM) +350 mg etesevimab (ETE) administered IV.</description>
        </group>
        <group group_id="B3">
          <title>Treatment 3: 700 mg BAM +1400 mg ETE</title>
          <description>Participants received 700 mg BAM +1400 mg ETE administered IV.</description>
        </group>
        <group group_id="B4">
          <title>Treatment 4: 2800 mg BAM +2800 mg ETE</title>
          <description>Participants received 2800 mg BAM + 2800 mg ETE administered IV.</description>
        </group>
        <group group_id="B5">
          <title>Treatment 5: 700 mg BAM</title>
          <description>Participants received 700 mg BAM administered IV.</description>
        </group>
        <group group_id="B6">
          <title>Treatment 6: 350 mg BAM +700 mg ETE</title>
          <description>Participants received 350 mg BAM +700 mg ETE administered IV.</description>
        </group>
        <group group_id="B7">
          <title>Unintentional Dosing: 700 mg Bamlanivimab +700 mg Etesevimab</title>
          <description>Participants received 700 mg bamlanivimab +700 mg etesevimab administered IV.</description>
        </group>
        <group group_id="B8">
          <title>Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
          <description>Participants received 700 mg BAM + 500 mg VIR-7831 administered IV.</description>
        </group>
        <group group_id="B9">
          <title>Treatment 8: Pbo For 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
          <description>Participants received placebo administered IV.</description>
        </group>
        <group group_id="B10">
          <title>Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants)</title>
          <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
        </group>
        <group group_id="B11">
          <title>Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants)</title>
          <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV</description>
        </group>
        <group group_id="B12">
          <title>Treatment 11: Pbo For 175 mg BEB &amp; 700 mg BAM +1400 mg ETE +175 mg BEB (Low Risk Participants)</title>
          <description>Amendment (f) Low Risk Participants:&#xD;
Participants received placebo administered IV.</description>
        </group>
        <group group_id="B13">
          <title>Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants)</title>
          <description>Amendment (f) High Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
        </group>
        <group group_id="B14">
          <title>Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants)</title>
          <description>Amendment (f) High Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
        </group>
        <group group_id="B15">
          <title>Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB (Amendment (g), Updated CDC Criteria)</title>
          <description>Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV for participants in updated CDC criteria.</description>
        </group>
        <group group_id="B16">
          <title>700 mg BAM 15-min (Addendum (2))</title>
          <description>Participants received 700 mg BAM administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
        </group>
        <group group_id="B17">
          <title>700 mg BAM + 1400 mg ETE 30-min (Addendum (2))</title>
          <description>Participants received 700 mg BAM +1400 mg ETE administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
        </group>
        <group group_id="B18">
          <title>700 mg BAM + 1400 mg ETE 15-min (Addendum (2))</title>
          <description>Participants received 700 mg BAM +1400 mg ETE administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
        </group>
        <group group_id="B19">
          <title>Pooled Placebo (Addendum 4, IV)</title>
          <description>Participants received placebo administered IV.</description>
        </group>
        <group group_id="B20">
          <title>70 mg BEB 140 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 70 mg BEB 140 mg/min IV.</description>
        </group>
        <group group_id="B21">
          <title>175 mg BEB 140 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 175 mg BEB 140 mg/min IV.</description>
        </group>
        <group group_id="B22">
          <title>175 mg BEB 350 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 175 mg BEB 350 mg/min IV.</description>
        </group>
        <group group_id="B23">
          <title>175/700/1400 mg BAM + ETE + BEB 350 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 175 mg BAM + 700 mg ETE + 1400 mg BEB 350 mg/min IV.</description>
        </group>
        <group group_id="B24">
          <title>1750 mg BEB 350 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 1750 mg BEB 350 mg/min IV.</description>
        </group>
        <group group_id="B25">
          <title>Pooled Placebo (Addendum 4, SC)</title>
          <description>Participants received Placebo SC.</description>
        </group>
        <group group_id="B26">
          <title>280 BEB (Addendum 4, SC)</title>
          <description>Participants received 280 mg BEB SC.</description>
        </group>
        <group group_id="B27">
          <title>560 mg BEB (Addendum 4, SC)</title>
          <description>Participants received 560 mg BEB SC.</description>
        </group>
        <group group_id="B28">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="83"/>
            <count group_id="B3" value="158"/>
            <count group_id="B4" value="103"/>
            <count group_id="B5" value="105"/>
            <count group_id="B6" value="101"/>
            <count group_id="B7" value="20"/>
            <count group_id="B8" value="101"/>
            <count group_id="B9" value="101"/>
            <count group_id="B10" value="125"/>
            <count group_id="B11" value="127"/>
            <count group_id="B12" value="128"/>
            <count group_id="B13" value="100"/>
            <count group_id="B14" value="50"/>
            <count group_id="B15" value="176"/>
            <count group_id="B16" value="30"/>
            <count group_id="B17" value="6"/>
            <count group_id="B18" value="30"/>
            <count group_id="B19" value="10"/>
            <count group_id="B20" value="6"/>
            <count group_id="B21" value="6"/>
            <count group_id="B22" value="6"/>
            <count group_id="B23" value="6"/>
            <count group_id="B24" value="6"/>
            <count group_id="B25" value="4"/>
            <count group_id="B26" value="6"/>
            <count group_id="B27" value="6"/>
            <count group_id="B28" value="1755"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.9" spread="12.22"/>
                    <measurement group_id="B2" value="41.5" spread="12.89"/>
                    <measurement group_id="B3" value="37.7" spread="12.11"/>
                    <measurement group_id="B4" value="39.5" spread="12.63"/>
                    <measurement group_id="B5" value="39.8" spread="12.70"/>
                    <measurement group_id="B6" value="42.3" spread="11.93"/>
                    <measurement group_id="B7" value="36.5" spread="15.04"/>
                    <measurement group_id="B8" value="37.6" spread="12.83"/>
                    <measurement group_id="B9" value="38.9" spread="11.77"/>
                    <measurement group_id="B10" value="36.2" spread="11.40"/>
                    <measurement group_id="B11" value="37.6" spread="12.12"/>
                    <measurement group_id="B12" value="36.1" spread="11.66"/>
                    <measurement group_id="B13" value="49.1" spread="15.17"/>
                    <measurement group_id="B14" value="50.8" spread="17.06"/>
                    <measurement group_id="B15" value="49.3" spread="17.39"/>
                    <measurement group_id="B16" value="35.4" spread="12.55"/>
                    <measurement group_id="B17" value="47.7" spread="7.28"/>
                    <measurement group_id="B18" value="42.9" spread="11.87"/>
                    <measurement group_id="B19" value="46.8" spread="13.27"/>
                    <measurement group_id="B20" value="35.2" spread="13.99"/>
                    <measurement group_id="B21" value="48.7" spread="9.83"/>
                    <measurement group_id="B22" value="36.3" spread="15.24"/>
                    <measurement group_id="B23" value="41.7" spread="14.76"/>
                    <measurement group_id="B24" value="39.5" spread="16.88"/>
                    <measurement group_id="B25" value="30.0" spread="6.98"/>
                    <measurement group_id="B26" value="35.8" spread="7.08"/>
                    <measurement group_id="B27" value="39.2" spread="9.70"/>
                    <measurement group_id="B28" value="40.6" spread="13.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="52"/>
                    <measurement group_id="B9" value="56"/>
                    <measurement group_id="B10" value="63"/>
                    <measurement group_id="B11" value="76"/>
                    <measurement group_id="B12" value="72"/>
                    <measurement group_id="B13" value="52"/>
                    <measurement group_id="B14" value="26"/>
                    <measurement group_id="B15" value="98"/>
                    <measurement group_id="B16" value="12"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="13"/>
                    <measurement group_id="B19" value="3"/>
                    <measurement group_id="B20" value="3"/>
                    <measurement group_id="B21" value="6"/>
                    <measurement group_id="B22" value="1"/>
                    <measurement group_id="B23" value="3"/>
                    <measurement group_id="B24" value="5"/>
                    <measurement group_id="B25" value="1"/>
                    <measurement group_id="B26" value="1"/>
                    <measurement group_id="B27" value="2"/>
                    <measurement group_id="B28" value="909"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="53"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="49"/>
                    <measurement group_id="B9" value="45"/>
                    <measurement group_id="B10" value="62"/>
                    <measurement group_id="B11" value="51"/>
                    <measurement group_id="B12" value="56"/>
                    <measurement group_id="B13" value="48"/>
                    <measurement group_id="B14" value="24"/>
                    <measurement group_id="B15" value="78"/>
                    <measurement group_id="B16" value="18"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="17"/>
                    <measurement group_id="B19" value="7"/>
                    <measurement group_id="B20" value="3"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="5"/>
                    <measurement group_id="B23" value="3"/>
                    <measurement group_id="B24" value="1"/>
                    <measurement group_id="B25" value="3"/>
                    <measurement group_id="B26" value="5"/>
                    <measurement group_id="B27" value="4"/>
                    <measurement group_id="B28" value="846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="27"/>
                    <measurement group_id="B10" value="46"/>
                    <measurement group_id="B11" value="45"/>
                    <measurement group_id="B12" value="45"/>
                    <measurement group_id="B13" value="19"/>
                    <measurement group_id="B14" value="8"/>
                    <measurement group_id="B15" value="49"/>
                    <measurement group_id="B16" value="15"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="3"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="1"/>
                    <measurement group_id="B23" value="1"/>
                    <measurement group_id="B24" value="2"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="1"/>
                    <measurement group_id="B27" value="2"/>
                    <measurement group_id="B28" value="497"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="74"/>
                    <measurement group_id="B6" value="66"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="80"/>
                    <measurement group_id="B9" value="72"/>
                    <measurement group_id="B10" value="78"/>
                    <measurement group_id="B11" value="82"/>
                    <measurement group_id="B12" value="83"/>
                    <measurement group_id="B13" value="81"/>
                    <measurement group_id="B14" value="42"/>
                    <measurement group_id="B15" value="126"/>
                    <measurement group_id="B16" value="15"/>
                    <measurement group_id="B17" value="5"/>
                    <measurement group_id="B18" value="26"/>
                    <measurement group_id="B19" value="6"/>
                    <measurement group_id="B20" value="6"/>
                    <measurement group_id="B21" value="6"/>
                    <measurement group_id="B22" value="5"/>
                    <measurement group_id="B23" value="5"/>
                    <measurement group_id="B24" value="4"/>
                    <measurement group_id="B25" value="4"/>
                    <measurement group_id="B26" value="2"/>
                    <measurement group_id="B27" value="4"/>
                    <measurement group_id="B28" value="1228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="3"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="19"/>
                    <measurement group_id="B11" value="19"/>
                    <measurement group_id="B12" value="29"/>
                    <measurement group_id="B13" value="14"/>
                    <measurement group_id="B14" value="13"/>
                    <measurement group_id="B15" value="28"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="1"/>
                    <measurement group_id="B27" value="1"/>
                    <measurement group_id="B28" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="85"/>
                    <measurement group_id="B6" value="84"/>
                    <measurement group_id="B7" value="17"/>
                    <measurement group_id="B8" value="74"/>
                    <measurement group_id="B9" value="90"/>
                    <measurement group_id="B10" value="97"/>
                    <measurement group_id="B11" value="99"/>
                    <measurement group_id="B12" value="90"/>
                    <measurement group_id="B13" value="78"/>
                    <measurement group_id="B14" value="32"/>
                    <measurement group_id="B15" value="136"/>
                    <measurement group_id="B16" value="27"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="27"/>
                    <measurement group_id="B19" value="9"/>
                    <measurement group_id="B20" value="6"/>
                    <measurement group_id="B21" value="6"/>
                    <measurement group_id="B22" value="6"/>
                    <measurement group_id="B23" value="6"/>
                    <measurement group_id="B24" value="6"/>
                    <measurement group_id="B25" value="4"/>
                    <measurement group_id="B26" value="5"/>
                    <measurement group_id="B27" value="5"/>
                    <measurement group_id="B28" value="1410"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                    <measurement group_id="B25" value="0"/>
                    <measurement group_id="B26" value="0"/>
                    <measurement group_id="B27" value="0"/>
                    <measurement group_id="B28" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="103"/>
                    <measurement group_id="B5" value="105"/>
                    <measurement group_id="B6" value="101"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="101"/>
                    <measurement group_id="B9" value="101"/>
                    <measurement group_id="B10" value="125"/>
                    <measurement group_id="B11" value="127"/>
                    <measurement group_id="B12" value="128"/>
                    <measurement group_id="B13" value="100"/>
                    <measurement group_id="B14" value="50"/>
                    <measurement group_id="B15" value="176"/>
                    <measurement group_id="B16" value="30"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="30"/>
                    <measurement group_id="B19" value="10"/>
                    <measurement group_id="B20" value="6"/>
                    <measurement group_id="B21" value="6"/>
                    <measurement group_id="B22" value="6"/>
                    <measurement group_id="B23" value="6"/>
                    <measurement group_id="B24" value="6"/>
                    <measurement group_id="B25" value="4"/>
                    <measurement group_id="B26" value="6"/>
                    <measurement group_id="B27" value="6"/>
                    <measurement group_id="B28" value="1755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Greater Than 5.27</title>
        <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Relevance Sequence Imputation (RSI). RSI is defined as follows: If Day 7 SARS-CoV-2 viral load is missing, then Day 7 will be imputed using data from the first available for Day 5, Day 3, Day 11, or Day 1.</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 1-6 and Unintentional Dosing arms: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: Pbo</title>
            <description>Participants received placebo (Pbo) administered intravenously (IV).</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 175 mg BAM +350 mg ETE</title>
            <description>Participants received 175 milligrams (mg) bamlanivimab (BAM) +350 mg etesevimab (ETE) administered IV.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 700 mg BAM +1400 mg ETE</title>
            <description>Participants received 700 mg BAM +1400 mg ETE administered IV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2800 mg BAM +2800 mg ETE</title>
            <description>Participants received 2800 mg BAM + 2800 mg ETE administered IV.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 700 mg BAM</title>
            <description>Participants received 700 mg BAM administered IV.</description>
          </group>
          <group group_id="O6">
            <title>Treatment 6: 350 mg BAM +700 mg ETE</title>
            <description>Participants received 350 mg BAM +700 mg ETE administered IV.</description>
          </group>
          <group group_id="O7">
            <title>Unintentional Dosing: 700 mg BAM +700 mg ETE</title>
            <description>Participants received 700 mg BAM +700 mg ETE administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Greater Than 5.27</title>
          <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Relevance Sequence Imputation (RSI). RSI is defined as follows: If Day 7 SARS-CoV-2 viral load is missing, then Day 7 will be imputed using data from the first available for Day 5, Day 3, Day 11, or Day 1.</description>
          <population>Treatment 1-6 and Unintentional Dosing arms: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="101"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" lower_limit="20.7" upper_limit="34.8"/>
                    <measurement group_id="O2" value="12.2" lower_limit="5.1" upper_limit="19.3"/>
                    <measurement group_id="O3" value="10.8" lower_limit="6.0" upper_limit="15.7"/>
                    <measurement group_id="O4" value="7.8" lower_limit="2.6" upper_limit="12.9"/>
                    <measurement group_id="O5" value="14.3" lower_limit="7.6" upper_limit="21.0"/>
                    <measurement group_id="O6" value="7.9" lower_limit="2.7" upper_limit="13.2"/>
                    <measurement group_id="O7" value="10.0" lower_limit="0.0" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009273</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000271</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000257</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013378</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000318</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140563</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment 7-8, Amendments (C-e): Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
        <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 7-8, Amendments (C-e): All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received 700 mg BAM + 500 mg VIR-7831 administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 8: Pbo For 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received placebo administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 7-8, Amendments (C-e): Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
          <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
          <population>Treatment 7-8, Amendments (C-e): All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="4.1" upper_limit="15.7"/>
                    <measurement group_id="O2" value="29.7" lower_limit="20.8" upper_limit="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000835</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
        <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 9-11 Amendment (f), Low Risk Participants: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 11: Pbo For 175 mg BEB &amp; 700 mg BAM +1400 mg ETE +175 mg BEB (Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received placebo administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
          <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
          <population>Treatment 9-11 Amendment (f), Low Risk Participants: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="6.3" upper_limit="17.7"/>
                    <measurement group_id="O2" value="12.7" lower_limit="6.9" upper_limit="18.5"/>
                    <measurement group_id="O3" value="19.8" lower_limit="12.9" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.097231</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.132360</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 12 -13, Amendment (f) High Risk Participants: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
        <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 12 -13, Amendment (f) High Risk Participants: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants)</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants)</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 12 -13, Amendment (f) High Risk Participants: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
          <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
          <population>Treatment 12 -13, Amendment (f) High Risk Participants: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" lower_limit="16.7" upper_limit="33.8"/>
                    <measurement group_id="O2" value="12.0" lower_limit="3.0" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 14, Amendment (f) High Risk Participants Updated CDC Criteria: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
        <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 14, Amendment (f) High Risk Participants Updated CDC Criteria: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB(Amendment (g), High Risk,Updated CDC Criteria)</title>
            <description>Amendment (g), High Risk, Updated CDC Criteria):&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV for participants in updated CDC criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 14, Amendment (f) High Risk Participants Updated CDC Criteria: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
          <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
          <population>Treatment 14, Amendment (f) High Risk Participants Updated CDC Criteria: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="12.0" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Addendum (2): Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
        <description>Missing data is estimated using Relevance Sequence Imputation (RSI). RSI is defined as follows: If Day 7 SARS-CoV-2 viral load is missing, then Day 7 will be imputed using data from the first available for Day 5, Day 3, Day 11, or Day 1.</description>
        <time_frame>Day 7</time_frame>
        <population>Addendum (2): All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>700 mg BAM 15-min (Addendum (2))</title>
            <description>Participants received 700 mg BAM administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
          </group>
          <group group_id="O2">
            <title>700 mg BAM + 1400 mg ETE 30-min (Addendum (2))</title>
            <description>Participants received 700 mg BAM +1400 mg ETE administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
          </group>
          <group group_id="O3">
            <title>700 mg BAM + 1400 mg ETE 15-min (Addendum (2))</title>
            <description>Participants received 700 mg BAM +1400 mg ETE administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
          </group>
        </group_list>
        <measure>
          <title>Addendum (2): Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
          <description>Missing data is estimated using Relevance Sequence Imputation (RSI). RSI is defined as follows: If Day 7 SARS-CoV-2 viral load is missing, then Day 7 will be imputed using data from the first available for Day 5, Day 3, Day 11, or Day 1.</description>
          <population>Addendum (2): All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="3.3" upper_limit="30.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="13.3" lower_limit="1.2" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Addendum (4), Arm A - Intravenous: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
        <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
        <time_frame>Day 7</time_frame>
        <population>Addendum (4) Arm A - Intravenous: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (Addendum 4, IV)</title>
            <description>Participants received placebo administered IV.</description>
          </group>
          <group group_id="O2">
            <title>70 mg BEB 140 mg/Min (Addendum 4, IV)</title>
            <description>Participants received 70 mg BEB 140 mg/min IV.</description>
          </group>
          <group group_id="O3">
            <title>175 BEB 140 mg/Min (Addendum 4, IV)</title>
            <description>Participants received 175 mg BEB 140 mg/min IV.</description>
          </group>
          <group group_id="O4">
            <title>175 BEB 350 mg/Min (Addendum 4, IV)</title>
            <description>Participants received 175 mg BEB 350 mg/min IV.</description>
          </group>
          <group group_id="O5">
            <title>175/700/1400 BAM+ETE+BEB 350mg/Min (Addendum 4, IV)</title>
            <description>Participants received 175 mg BAM + 700 mg ETE + 1400 mg BEB 350 mg/min IV.</description>
          </group>
          <group group_id="O6">
            <title>1750 BEB 350 mg/Min (Addendum 4, IV)</title>
            <description>Participants received 1750 mg BEB 350 mg/min IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Addendum (4), Arm A - Intravenous: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
          <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
          <population>Addendum (4) Arm A - Intravenous: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="9.6" upper_limit="70.4"/>
                    <measurement group_id="O2" value="16.7" lower_limit="0.0" upper_limit="46.5"/>
                    <measurement group_id="O3" value="50.0" lower_limit="10.0" upper_limit="90.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="16.7" lower_limit="0.0" upper_limit="46.5"/>
                    <measurement group_id="O6" value="33.3" lower_limit="0.0" upper_limit="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Addendum (4) Arm B - Subcutaneous: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
        <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
        <time_frame>Day 7</time_frame>
        <population>Addendum (4) Arm B - Subcutaneous: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (Addendum 4, SC)</title>
            <description>Participants received placebo administered SC.</description>
          </group>
          <group group_id="O2">
            <title>280 mg BEB (Addendum 4, SC)</title>
            <description>Participants received 280 mg BEB SC.</description>
          </group>
          <group group_id="O3">
            <title>560 mg BEB (Addendum 4, SC)</title>
            <description>Participants received 560 mg BEB SC.</description>
          </group>
        </group_list>
        <measure>
          <title>Addendum (4) Arm B - Subcutaneous: Percentage of Participants With SARS-CoV-2 Viral Load Greater Than 5.27</title>
          <description>Percentage of participants with SARS-CoV-2 viral load greater than 5.27 on Day 7. Missing data is estimated using Last Observation Carried Forward (LOCF).</description>
          <population>Addendum (4) Arm B - Subcutaneous: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="0.0" upper_limit="67.4"/>
                    <measurement group_id="O2" value="16.7" lower_limit="0.0" upper_limit="46.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</title>
        <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death from any Cause</description>
        <time_frame>Baseline through Day 29</time_frame>
        <population>Treatment 1-6 and Unintentional Dosing arms: All participants randomly assigned and who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: Pbo</title>
            <description>Participants received placebo (Pbo) administered intravenously (IV).</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 175 mg BAM +350 mg ETE</title>
            <description>Participants received 175 milligrams (mg) bamlanivimab (BAM) +350 mg etesevimab (ETE) administered IV.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 700 mg BAM +1400 mg ETE</title>
            <description>Participants received 700 mg BAM +1400 mg ETE administered IV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2800 mg BAM +2800 mg ETE</title>
            <description>Participants received 2800 mg BAM + 2800 mg ETE administered IV.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 700 mg BAM</title>
            <description>Participants received 700 mg BAM administered IV.</description>
          </group>
          <group group_id="O6">
            <title>Treatment 6: 350 mg BAM +700 mg ETE</title>
            <description>Participants received 350 mg BAM +700 mg ETE administered IV.</description>
          </group>
          <group group_id="O7">
            <title>Unintentional Dosing: 700 mg Bamlanivimab +700 mg Etesevimab</title>
            <description>Participants received 700 mg bamlanivimab +700 mg etesevimab administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</title>
          <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death from any Cause</description>
          <population>Treatment 1-6 and Unintentional Dosing arms: All participants randomly assigned and who received any amount of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="101"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.0" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O7" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.769</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>15.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.494</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>8.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.671</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>12.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.663</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>12.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.680</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>12.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.584</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>67.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 7-8, Amendment (C-E): Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</title>
        <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death from Any Cause</description>
        <time_frame>Baseline through Day 29</time_frame>
        <population>Treatment 7-8, Amendment (C-E): All participants randomly assigned and who received any amount of study drug. No participants met the criteria (duration had to be 24 or more, and had to occur on Day 29 or before)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received 700 mg BAM + 500 mg VIR-7831 administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 8: Pbo For 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received placebo administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 7-8, Amendment (C-E): Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</title>
          <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death from Any Cause</description>
          <population>Treatment 7-8, Amendment (C-E): All participants randomly assigned and who received any amount of study drug. No participants met the criteria (duration had to be 24 or more, and had to occur on Day 29 or before)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</title>
        <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</description>
        <time_frame>Baseline through Day 29</time_frame>
        <population>Treatment 9-11 Amendment (f), Low Risk Participants: All randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 11: Pbo For 175 mg BEB &amp; 700 mg BAM +1400 mg ETE +175 mg BEB (Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received placebo administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</title>
          <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</description>
          <population>Treatment 9-11 Amendment (f), Low Risk Participants: All randomized participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.0" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.979</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>6.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>7.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</title>
        <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</description>
        <time_frame>Baseline through Day 29</time_frame>
        <population>Treatment 12 -13 Amendment (f), High Risk Participants: All randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants)</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</title>
          <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</description>
          <population>Treatment 12 -13 Amendment (f), High Risk Participants: All randomized participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="4.0" lower_limit="0.0" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 14 Amendment (f) High Risk Participants, Updated CDC Criteria: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</title>
        <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</description>
        <time_frame>Baseline through Day 29</time_frame>
        <population>Treatment 14 Amendment (f) High Risk, Participants Updated CDC Criteria: All randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB (Amendment (g) High Risk,Updated CDC Criteria)</title>
            <description>Amendment (g), High Risk, Updated CDC Criteria):&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV for participants in updated CDC criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 14 Amendment (f) High Risk Participants, Updated CDC Criteria: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</title>
          <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause</description>
          <population>Treatment 14 Amendment (f) High Risk, Participants Updated CDC Criteria: All randomized participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="0.0" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 1-6 and Unintentional Dosing Arms: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
        <description>Least squares mean (LSM) change from baseline was calculated using a mixed model repeating measures (MMRM) that included log base 10 transformed baseline as a covariate, treatment, day, treatment-by-day interaction as fixed effects. Viral load is reported as normalized viral and is unitless.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Treatment 1-6 and Unintentional Dosing Arms: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: Pbo</title>
            <description>Participants received placebo (Pbo) administered intravenously (IV).</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 175 mg BAM +350 mg ETE</title>
            <description>Participants received 175 milligrams (mg) bamlanivimab (BAM) +350 mg etesevimab (ETE) administered IV.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 700 mg BAM +1400 mg ETE</title>
            <description>Participants received 700 mg BAM +1400 mg ETE administered IV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2800 mg BAM +2800 mg ETE</title>
            <description>Participants received 2800 mg BAM + 2800 mg ETE administered IV.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 700 mg BAM</title>
            <description>Participants received 700 mg BAM administered IV.</description>
          </group>
          <group group_id="O6">
            <title>Treatment 6: 350 mg BAM +700 mg ETE</title>
            <description>Participants received 350 mg BAM +700 mg ETE administered IV.</description>
          </group>
          <group group_id="O7">
            <title>Unintentional Dosing: 700 mg Bamlanivimab +700 mg Etesevimab</title>
            <description>Participants received 700 mg bamlanivimab +700 mg etesevimab administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 1-6 and Unintentional Dosing Arms: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
          <description>Least squares mean (LSM) change from baseline was calculated using a mixed model repeating measures (MMRM) that included log base 10 transformed baseline as a covariate, treatment, day, treatment-by-day interaction as fixed effects. Viral load is reported as normalized viral and is unitless.</description>
          <population>Treatment 1-6 and Unintentional Dosing Arms: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>unitless</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="81"/>
                <count group_id="O7" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.87" spread="0.149"/>
                    <measurement group_id="O2" value="-3.54" spread="0.207"/>
                    <measurement group_id="O3" value="-3.52" spread="0.148"/>
                    <measurement group_id="O4" value="-3.13" spread="0.181"/>
                    <measurement group_id="O5" value="-3.28" spread="0.180"/>
                    <measurement group_id="O6" value="-3.74" spread="0.191"/>
                    <measurement group_id="O7" value="-3.51" spread="0.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.17</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.06</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.263</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.149</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.52</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 7-8 Amendments (C-e): Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
        <description>LSM change from baseline was calculated using a MMRM that included log base 10 transformed baseline as a covariate, treatment, day, treatment-by-day interaction as fixed effects. Viral load is reported as normalized viral and is unitless.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Treatment 7-8 Amendments (c-e): All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received 700 mg BAM + 500 mg VIR-7831 administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 8: Pbo For 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received placebo administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 7-8 Amendments (C-e): Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
          <description>LSM change from baseline was calculated using a MMRM that included log base 10 transformed baseline as a covariate, treatment, day, treatment-by-day interaction as fixed effects. Viral load is reported as normalized viral and is unitless.</description>
          <population>Treatment 7-8 Amendments (c-e): All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>unitless</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.56" spread="0.182"/>
                    <measurement group_id="O2" value="-2.74" spread="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.33</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 9-11 Amendment (f), Low Risk Participants: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
        <description>LSM change from baseline was calculated using a MMRM that included log base 10 transformed baseline as a covariate, treatment, day, treatment-by-day interaction as fixed effects. Viral load is reported as normalized viral and is unitless.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Treatment 9-11 Amendment (f), Low Risk Participants: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 11: Pbo For 175 mg BEB &amp; 700 mg BAM +1400 mg ETE +175 mg BEB (Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received placebo administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 9-11 Amendment (f), Low Risk Participants: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
          <description>LSM change from baseline was calculated using a MMRM that included log base 10 transformed baseline as a covariate, treatment, day, treatment-by-day interaction as fixed effects. Viral load is reported as normalized viral and is unitless.</description>
          <population>Treatment 9-11 Amendment (f), Low Risk Participants: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>unitless</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.77" spread="0.198"/>
                    <measurement group_id="O2" value="-4.00" spread="0.196"/>
                    <measurement group_id="O3" value="-3.62" spread="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.606</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.170</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSM Difference</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 12 -13 Amendment (f), High Risk Participants: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
        <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Treatment 12 -13 Amendment (f), High Risk Participants: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants)</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants)</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 12 -13 Amendment (f), High Risk Participants: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
          <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
          <population>Treatment 12 -13 Amendment (f), High Risk Participants: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.22" spread="2.585"/>
                    <measurement group_id="O2" value="-3.43" spread="2.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 14, Amendment (f) High Risk Participants Updated CDC Criteria: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
        <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Treatment 14, Amendment (f) High Risk Participants Updated CDC Criteria: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB(Amendment (g), High Risk,Updated CDC Criteria)</title>
            <description>Amendment (g), High Risk, Updated CDC Criteria):&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV for participants in updated CDC criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 14, Amendment (f) High Risk Participants Updated CDC Criteria: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
          <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
          <population>Treatment 14, Amendment (f) High Risk Participants Updated CDC Criteria: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.00" spread="2.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Addendum 4, IV: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
        <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Addendum 4, IV: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (Addendum 4, IV)</title>
            <description>Participants received placebo administered IV.</description>
          </group>
          <group group_id="O2">
            <title>70 mg BEB 140 mg/Min (Addendum 4, IV)</title>
            <description>Participants received 70 mg BEB 140 mg/min IV.</description>
          </group>
          <group group_id="O3">
            <title>175 BEB 140 mg/Min (Addendum 4, IV)</title>
            <description>Participants received 175 mg BEB 140 mg/min IV.</description>
          </group>
          <group group_id="O4">
            <title>175 BEB 350 mg/Min (Addendum 4, IV)</title>
            <description>Participants received 175 mg BEB 350 mg/min IV.</description>
          </group>
          <group group_id="O5">
            <title>175/700/1400 BAM+ETE+BEB 350mg/Min (Addendum 4, IV)</title>
            <description>Participants received 175 mg BAM + 700 mg ETE + 1400 mg BEB 350 mg/min IV.</description>
          </group>
          <group group_id="O6">
            <title>1750 BEB 350 mg/Min (Addendum 4, IV)</title>
            <description>Participants received 1750 mg BEB 350 mg/min IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Addendum 4, IV: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
          <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
          <population>Addendum 4, IV: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.27" spread="3.087"/>
                    <measurement group_id="O2" value="-4.39" spread="2.334"/>
                    <measurement group_id="O3" value="-4.40" spread="3.188"/>
                    <measurement group_id="O4" value="-4.49" spread="1.925"/>
                    <measurement group_id="O5" value="-6.35" spread="1.502"/>
                    <measurement group_id="O6" value="-4.76" spread="2.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Addendum 4, SC: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
        <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Addendum 4, SC: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo (Addendum 4, SC)</title>
            <description>Participants received Placebo SC.</description>
          </group>
          <group group_id="O2">
            <title>280 mg BEB (Addendum 4, SC)</title>
            <description>Participants received 280 mg BEB SC.</description>
          </group>
          <group group_id="O3">
            <title>560 mg BEB (Addendum 4, SC</title>
            <description>Participants received 560 mg BEB SC.</description>
          </group>
        </group_list>
        <measure>
          <title>Addendum 4, SC: Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
          <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
          <population>Addendum 4, SC: All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.47" spread="3.934"/>
                    <measurement group_id="O2" value="-4.04" spread="2.114"/>
                    <measurement group_id="O3" value="-3.40" spread="1.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Addendum (2): Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
        <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Addendum (2): All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>700 mg BAM 15-min (Addendum (2))</title>
            <description>Participants received 700 mg BAM administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
          </group>
          <group group_id="O2">
            <title>700 mg BAM + 1400 mg ETE 30-min (Addendum (2))</title>
            <description>Participants received 700 mg BAM +1400 mg ETE administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
          </group>
          <group group_id="O3">
            <title>700 mg BAM + 1400 mg ETE 15-min (Addendum (2))</title>
            <description>Participants received 700 mg BAM +1400 mg ETE administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
          </group>
        </group_list>
        <measure>
          <title>Addendum (2): Change From Baseline to Day 7 in SARS-CoV-2 Viral Load</title>
          <description>Baseline is defined as the last non-missing assessment recorded on or prior to the date of first study drug injection. Viral load is reported as normalized viral and is unitless.</description>
          <population>Addendum (2): All randomized participants who received study drug and provided at least 1 postbaseline measure viral load measurement.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.65" spread="2.394"/>
                    <measurement group_id="O2" value="-4.90" spread="1.999"/>
                    <measurement group_id="O3" value="-4.37" spread="2.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Demonstrating Symptom Resolution</title>
        <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as all symptoms (excluding loss of appetite, taste, and smell) on the symptom questionnaire scored as absent (score of 0). Missing data was imputed using a non-responder imputation.</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 1-6 and Unintentional Dosing Arms: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Resolution values.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: Pbo</title>
            <description>Participants received placebo (Pbo) administered intravenously (IV).</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 175 mg BAM +350 mg ETE</title>
            <description>Participants received 175 milligrams (mg) bamlanivimab (BAM) +350 mg etesevimab (ETE) administered IV.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 700 mg BAM +1400 mg ETE</title>
            <description>Participants received 700 mg BAM +1400 mg ETE administered IV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2800 mg BAM +2800 mg ETE</title>
            <description>Participants received 2800 mg BAM + 2800 mg ETE administered IV.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 700 mg BAM</title>
            <description>Participants received 700 mg BAM administered IV.</description>
          </group>
          <group group_id="O6">
            <title>Treatment 6: 350 mg BAM +700 mg ETE</title>
            <description>Participants received 350 mg BAM +700 mg ETE administered IV.</description>
          </group>
          <group group_id="O7">
            <title>Unintentional Dosing: 700 mg Bamlanivimab +700 mg Etesevimab</title>
            <description>Participants received 700 mg bamlanivimab +700 mg etesevimab administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Demonstrating Symptom Resolution</title>
          <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as all symptoms (excluding loss of appetite, taste, and smell) on the symptom questionnaire scored as absent (score of 0). Missing data was imputed using a non-responder imputation.</description>
          <population>Treatment 1-6 and Unintentional Dosing Arms: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Resolution values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="101"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="21.9" upper_limit="36.2"/>
                    <measurement group_id="O2" value="28.0" lower_limit="18.3" upper_limit="37.8"/>
                    <measurement group_id="O3" value="36.9" lower_limit="29.4" upper_limit="44.5"/>
                    <measurement group_id="O4" value="32.0" lower_limit="23.0" upper_limit="41.1"/>
                    <measurement group_id="O5" value="41.0" lower_limit="31.5" upper_limit="50.4"/>
                    <measurement group_id="O6" value="32.7" lower_limit="23.5" upper_limit="41.8"/>
                    <measurement group_id="O7" value="30.0" lower_limit="9.9" upper_limit="50.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.890</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.141</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>2.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.603</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>2.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.533</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.869</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 7-8 Amendments (C-e): Percentage of Participants Demonstrating Symptom Resolution</title>
        <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as all symptoms (excluding loss of appetite, taste, and smell) on the symptom questionnaire scored as absent (score of 0). Missing data was imputed using a non-responder imputation.</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 7-8 Amendments (c-e): All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Resolution values.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received 700 mg BAM + 500 mg VIR-7831 administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 8: Pbo For 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received placebo administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 7-8 Amendments (C-e): Percentage of Participants Demonstrating Symptom Resolution</title>
          <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as all symptoms (excluding loss of appetite, taste, and smell) on the symptom questionnaire scored as absent (score of 0). Missing data was imputed using a non-responder imputation.</description>
          <population>Treatment 7-8 Amendments (c-e): All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Resolution values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" lower_limit="26.3" upper_limit="45.0"/>
                    <measurement group_id="O2" value="29.7" lower_limit="20.8" upper_limit="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.374</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Demonstrating Symptom Resolution</title>
        <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as a score of 0 for shortness of breath, feeling feverish, body aches and pains, sore throat, chills, and headache, and a score of 0 or 1 for cough and fatigue on the symptom questionnaire. Missing data was imputed using a non-responder imputation.</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 9-11 Amendment (f), Low Risk Participants: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Resolution values.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 11: Pbo For 175 mg BEB &amp; 700 mg BAM +1400 mg ETE +175 mg BEB (Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received placebo administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Demonstrating Symptom Resolution</title>
          <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as a score of 0 for shortness of breath, feeling feverish, body aches and pains, sore throat, chills, and headache, and a score of 0 or 1 for cough and fatigue on the symptom questionnaire. Missing data was imputed using a non-responder imputation.</description>
          <population>Treatment 9-11 Amendment (f), Low Risk Participants: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Resolution values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="51.4" upper_limit="68.6"/>
                    <measurement group_id="O2" value="50.8" lower_limit="42.1" upper_limit="59.5"/>
                    <measurement group_id="O3" value="44.4" lower_limit="35.8" upper_limit="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>3.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.317</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Demonstrating Symptom Resolution</title>
        <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as a score of 0 for shortness of breath, feeling feverish, body aches and pains, sore throat, chills, and headache, and a score of 0 or 1 for cough and fatigue on the symptom questionnaire. Missing data was imputed using a non-responder imputation.</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 12 -13 Amendment (f), High Risk Participants: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Resolution values.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants)</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants)</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Demonstrating Symptom Resolution</title>
          <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as a score of 0 for shortness of breath, feeling feverish, body aches and pains, sore throat, chills, and headache, and a score of 0 or 1 for cough and fatigue on the symptom questionnaire. Missing data was imputed using a non-responder imputation.</description>
          <population>Treatment 12 -13 Amendment (f), High Risk Participants: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Resolution values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" lower_limit="40.7" upper_limit="60.4"/>
                    <measurement group_id="O2" value="52.0" lower_limit="38.2" upper_limit="65.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 14, Amendment (g) High Risk Participants Updated CDC Criteria Amendment (g): Percentage of Participants Demonstrating Symptom Resolution</title>
        <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as a score of 0 for shortness of breath, feeling feverish, body aches and pains, sore throat, chills, and headache, and a score of 0 or 1 for cough and fatigue on the symptom questionnaire. Missing data was imputed using a non-responder imputation.</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 14, Amendment (g) High Risk Participants Updated CDC Criteria Amendment (g): All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Resolution values.</population>
        <group_list>
          <group group_id="O1">
            <title>700 mg BAM + 1400 mg ETE + 175 mg BEB (Amendment (g))</title>
            <description>Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 14, Amendment (g) High Risk Participants Updated CDC Criteria Amendment (g): Percentage of Participants Demonstrating Symptom Resolution</title>
          <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom resolution (yes/no) is defined as a score of 0 for shortness of breath, feeling feverish, body aches and pains, sore throat, chills, and headache, and a score of 0 or 1 for cough and fatigue on the symptom questionnaire. Missing data was imputed using a non-responder imputation.</description>
          <population>Treatment 14, Amendment (g) High Risk Participants Updated CDC Criteria Amendment (g): All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Resolution values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2" lower_limit="39.8" upper_limit="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Demonstrating Symptom Improvement</title>
        <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 1-6 and Unintentional Dosing Arms: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Improvement values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo administered intravenously (IV).</description>
          </group>
          <group group_id="O2">
            <title>175 mg Bamlanivimab +350 mg Etesevimab</title>
            <description>Participants received 175 milligrams (mg) bamlanivimab +350 mg etesevimab administered IV.</description>
          </group>
          <group group_id="O3">
            <title>350 mg Bamlanivimab +700 mg Etesevimab</title>
            <description>Participants received 350 mg bamlanivimab +700 mg etesevimab administered IV.</description>
          </group>
          <group group_id="O4">
            <title>700 mg Bamlanivimab +1400 mg Etesevimab</title>
            <description>Participants received 700 mg bamlanivimab +1400 mg etesevimab administered IV.</description>
          </group>
          <group group_id="O5">
            <title>2800 mg Bamlanivimab +2800 mg Etesevimab</title>
            <description>Participants received 2800 mg bamlanivimab + 2800 mg etesevimab administered IV.</description>
          </group>
          <group group_id="O6">
            <title>700 mg Bamlanivimab</title>
            <description>Participants received 700 mg bamlanivimab administered IV.</description>
          </group>
          <group group_id="O7">
            <title>Unintentional Dosing Arm: 700 mg Bamlanivimab +700 mg Etesevimab</title>
            <description>Participants received 700 mg bamlanivimab +700 mg etesevimab administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Demonstrating Symptom Improvement</title>
          <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
          <population>Treatment 1-6 and Unintentional Dosing Arms: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Improvement values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="157"/>
                <count group_id="O5" value="103"/>
                <count group_id="O6" value="105"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" lower_limit="26.1" upper_limit="41.8"/>
                    <measurement group_id="O2" value="45.1" lower_limit="34.4" upper_limit="55.9"/>
                    <measurement group_id="O3" value="48.5" lower_limit="38.8" upper_limit="58.3"/>
                    <measurement group_id="O4" value="46.5" lower_limit="38.7" upper_limit="54.3"/>
                    <measurement group_id="O5" value="49.5" lower_limit="39.9" upper_limit="59.2"/>
                    <measurement group_id="O6" value="52.4" lower_limit="42.8" upper_limit="61.9"/>
                    <measurement group_id="O7" value="40.0" lower_limit="18.5" upper_limit="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>2.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>3.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>3.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>3.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.546</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>3.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 7-8 Amendments (C-E): Percentage of Participants Demonstrating Symptom Improvement</title>
        <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 7-8 Amendments (C-E): All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Improvement values.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received 700 mg BAM + 500 mg VIR-7831 administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 8: Pbo For 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received placebo administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 7-8 Amendments (C-E): Percentage of Participants Demonstrating Symptom Improvement</title>
          <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
          <population>Treatment 7-8 Amendments (C-E): All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Improvement values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" lower_limit="33.9" upper_limit="53.2"/>
                    <measurement group_id="O2" value="42.6" lower_limit="32.9" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.888</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Demonstrating Symptom Improvement</title>
        <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 9-11 Amendment (f), Low Risk Participants: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and and had non-missing Symptom Improvement values.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 11: Pbo For 175 mg BEB &amp; 700 mg BAM +1400 mg ETE +175 mg BEB (Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received placebo administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Demonstrating Symptom Improvement</title>
          <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
          <population>Treatment 9-11 Amendment (f), Low Risk Participants: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and and had non-missing Symptom Improvement values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" lower_limit="26.6" upper_limit="43.2"/>
                    <measurement group_id="O2" value="50.4" lower_limit="41.6" upper_limit="59.2"/>
                    <measurement group_id="O3" value="46.8" lower_limit="38.1" upper_limit="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>3.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.057</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>2.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Demonstrating Symptom Improvement</title>
        <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 12 -13 Amendment (f), High Risk Participants: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Improvement values.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants)</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants)</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Demonstrating Symptom Improvement</title>
          <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
          <population>Treatment 12 -13 Amendment (f), High Risk Participants: All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Improvement values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" lower_limit="32.7" upper_limit="52.2"/>
                    <measurement group_id="O2" value="42.0" lower_limit="28.3" upper_limit="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 14 Amendment (g): Percentage of Participants Demonstrating Symptom Improvement</title>
        <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
        <time_frame>Day 7</time_frame>
        <population>Treatment 14 Amendment (g): All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Improvement values.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB(Amendment (g), High Risk,Updated CDC Criteria)</title>
            <description>Amendment (g), High Risk, Updated CDC Criteria):&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV for participants in updated CDC criteria..</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 14 Amendment (g): Percentage of Participants Demonstrating Symptom Improvement</title>
          <description>Symptoms associated with COVID-19 were evaluated using a questionnaire that contains the following symptoms: cough, shortness of breath, feeling feverish, fatigue, body aches and pain, sore throat, chills, headache, loss of appetite, and loss in taste and smell. Each symptom (excluding loss of taste and smell) was scored daily by the participant as experienced during the past 24 hours with following rating and score: None or absent (0), Mild (1), Moderate (2) and Severe (3). Loss of taste and smell was scored as Yes (Y) or No (N). Symptom improvement (yes/no) is defined as a patient experiencing symptoms on the symptom questionnaire (excluding loss of appetite, taste, and smell) scored as moderate or severe (score of 2 or 3) at baseline are subsequently scored as mild or absent (score of 1 or 0), AND symptoms on the symptom questionnaire scored as mild or absent at baseline are subsequently scored as absent.</description>
          <population>Treatment 14 Amendment (g): All randomized participants who received study drug, provided at least 1 postbaseline measure viral load measurement and had non-missing Symptom Improvement values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" lower_limit="31.4" upper_limit="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</title>
        <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
        <time_frame>Baseline through Day 29</time_frame>
        <population>Treatment 1-6 and Unintentional Dosing Arms: All participants randomly assigned and who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1: Pbo</title>
            <description>Participants received placebo (Pbo) administered intravenously (IV).</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2: 175 mg BAM +350 mg ETE</title>
            <description>Participants received 175 milligrams (mg) bamlanivimab (BAM) +350 mg etesevimab (ETE) administered IV.</description>
          </group>
          <group group_id="O3">
            <title>Treatment 3: 700 mg BAM +1400 mg ETE</title>
            <description>Participants received 700 mg BAM +1400 mg ETE administered IV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment 4: 2800 mg BAM +2800 mg ETE</title>
            <description>Participants received 2800 mg BAM + 2800 mg ETE administered IV.</description>
          </group>
          <group group_id="O5">
            <title>Treatment 5: 700 mg BAM</title>
            <description>Participants received 700 mg BAM administered IV.</description>
          </group>
          <group group_id="O6">
            <title>Treatment 6: 350 mg BAM +700 mg ETE</title>
            <description>Participants received 350 mg BAM +700 mg ETE administered IV.</description>
          </group>
          <group group_id="O7">
            <title>Unintentional Dosing: 700 mg Bamlanivimab +700 mg Etesevimab</title>
            <description>Participants received 700 mg bamlanivimab +700 mg etesevimab administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</title>
          <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
          <population>Treatment 1-6 and Unintentional Dosing Arms: All participants randomly assigned and who received any amount of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="101"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.0" upper_limit="4.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.0" upper_limit="2.8"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O7" value="5.0" lower_limit="0.0" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 7-8 Amendments (C-E): Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</title>
        <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
        <time_frame>Baseline through Day 29</time_frame>
        <population>Treatment 7-8 Amendment (C-E): No participants met the criteria (duration had to be 24 or more, and had to occur on Day 29 or before).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received 700 mg BAM + 500 mg VIR-7831 administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 8: Pbo For 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
            <description>Participants received placebo administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 7-8 Amendments (C-E): Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</title>
          <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
          <population>Treatment 7-8 Amendment (C-E): No participants met the criteria (duration had to be 24 or more, and had to occur on Day 29 or before).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.0" upper_limit="2.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</title>
        <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
        <time_frame>Baseline through Day 29</time_frame>
        <population>Treatment 9-11 Amendment (f), Low Risk Participants: All participants randomly assigned and who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV..</description>
          </group>
          <group group_id="O3">
            <title>Treatment 11: Pbo For 175 mg BEB &amp; 700 mg BAM +1400 mg ETE +175 mg BEB (Low Risk Participants)</title>
            <description>Amendment (f) Low Risk Participants:&#xD;
Participants received placebo administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 9-11 Amendment (f), Low Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</title>
          <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
          <population>Treatment 9-11 Amendment (f), Low Risk Participants: All participants randomly assigned and who received any amount of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.0" upper_limit="3.8"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.0" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</title>
        <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
        <time_frame>Baseline through Day 29</time_frame>
        <population>Treatment 12 -13 Amendment (f), High Risk Participants: All participants randomly assigned and who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants)</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
          </group>
          <group group_id="O2">
            <title>Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants)</title>
            <description>Amendment (f) High Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 12 -13 Amendment (f), High Risk Participants: Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</title>
          <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
          <population>Treatment 12 -13 Amendment (f), High Risk Participants: All participants randomly assigned and who received any amount of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="1.3" upper_limit="10.7"/>
                    <measurement group_id="O2" value="6.0" lower_limit="0.0" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment 14 Amendment (g): Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</title>
        <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
        <time_frame>Baseline through Day 29</time_frame>
        <population>Treatment 14 Amendment (g): All participants randomly assigned and who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB(Amendment (g), High Risk,Updated CDC Criteria)</title>
            <description>Amendment (g), High Risk, Updated CDC Criteria):&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV for participants in updated CDC criteria.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment 14 Amendment (g): Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</title>
          <description>Percentage of Participants Who Experience COVID-19 Related Hospitalization, COVID-19 Related Emergency Room Visit, or Death From Any Cause</description>
          <population>Treatment 14 Amendment (g): All participants randomly assigned and who received any amount of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.1" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Mean Concentration of Bamlanivimab</title>
        <description>PK: Mean Concentration of Bamlanivimab</description>
        <time_frame>Day 29</time_frame>
        <population>All randomized participants who received 700 mg BAM and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>700 mg BAM</title>
            <description>Participants received 700 mg BAM administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Mean Concentration of Bamlanivimab</title>
          <description>PK: Mean Concentration of Bamlanivimab</description>
          <population>All randomized participants who received 700 mg BAM and had evaluable PK data.</population>
          <units>Microgram/milliliter (µg/mL)</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Mean Concentration of Etesevimab</title>
        <description>Pharmacokinetics (PK): Mean Concentration of Etesevimab</description>
        <time_frame>Day 29</time_frame>
        <population>All randomized participants who received 1400 ETE and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>1400 mg ETE</title>
            <description>Participants received 1400 mg ETE administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Mean Concentration of Etesevimab</title>
          <description>Pharmacokinetics (PK): Mean Concentration of Etesevimab</description>
          <population>All randomized participants who received 1400 ETE and had evaluable PK data.</population>
          <units>µg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Mean Concentration of Bebtelovimab</title>
        <description>Pharmacokinetics (PK): Mean Concentration of Bebtelovimab</description>
        <time_frame>Day 29</time_frame>
        <population>All randomized participants who received 175 mg BEB and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>175 mg BEB</title>
            <description>Participants received 175 mg BEB administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Mean Concentration of Bebtelovimab</title>
          <description>Pharmacokinetics (PK): Mean Concentration of Bebtelovimab</description>
          <population>All randomized participants who received 175 mg BEB and had evaluable PK data.</population>
          <units>µg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="520"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Mean Concentration of VIR-7831</title>
        <description>PK: Mean Concentration of VIR-7831</description>
        <time_frame>Day 29</time_frame>
        <population>All randomized participants who received 500 mg VIR-7831 and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>500 mg VIR-7831</title>
            <description>Participants received 500 mg VIR-7831 administered IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Mean Concentration of VIR-7831</title>
          <description>PK: Mean Concentration of VIR-7831</description>
          <population>All randomized participants who received 500 mg VIR-7831 and had evaluable PK data.</population>
          <units>µg/mL</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3" spread="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline Up To 169 Days</time_frame>
      <desc>All participants who received at least one dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment 1: Pbo</title>
          <description>Participants received placebo (Pbo) administered intravenously (IV).</description>
        </group>
        <group group_id="E2">
          <title>Treatment 2: 175 mg BAM +350 mg ETE</title>
          <description>Participants received 175 milligrams (mg) bamlanivimab (BAM) +350 mg etesevimab (ETE) administered IV.</description>
        </group>
        <group group_id="E3">
          <title>Treatment 3: 700 mg BAM +1400 mg ETE</title>
          <description>Participants received 700 mg BAM +1400 mg ETE administered IV.</description>
        </group>
        <group group_id="E4">
          <title>Treatment 4: 2800 mg BAM +2800 mg ETE</title>
          <description>Participants received 2800 mg BAM + 2800 mg ETE administered IV.</description>
        </group>
        <group group_id="E5">
          <title>Treatment 5: 700 mg BAM</title>
          <description>Participants received 700 mg BAM administered IV.</description>
        </group>
        <group group_id="E6">
          <title>Treatment 6: 350 mg BAM +700 mg ETE</title>
          <description>Participants received 350 mg BAM +700 mg ETE administered IV.</description>
        </group>
        <group group_id="E7">
          <title>Unintentional Dosing: 700 mg BAM +700 mg ETE</title>
          <description>Participants received 700 mg BAM +700 mg ETE administered IV.</description>
        </group>
        <group group_id="E8">
          <title>Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
          <description>Participants received 700 mg BAM + 500 mg VIR-7831 administered IV.</description>
        </group>
        <group group_id="E9">
          <title>Treatment 8: Pbo For 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e))</title>
          <description>Participants received placebo administered IV.</description>
        </group>
        <group group_id="E10">
          <title>Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants)</title>
          <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
        </group>
        <group group_id="E11">
          <title>Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants)</title>
          <description>Amendment (f) Low Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV</description>
        </group>
        <group group_id="E12">
          <title>Treatment 11: Pbo For 175 mg BEB &amp; 700 mg BAM +1400 mg ETE +175 mg BEB (Low Risk Participants)</title>
          <description>Amendment (f) Low Risk Participants:&#xD;
Participants received placebo administered IV.</description>
        </group>
        <group group_id="E13">
          <title>Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants)</title>
          <description>Amendment (f) High Risk Participants:&#xD;
Participants received 175 mg BEB administered IV.</description>
        </group>
        <group group_id="E14">
          <title>Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants)</title>
          <description>Amendment (f) High Risk Participants:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
        </group>
        <group group_id="E15">
          <title>Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB (Amendment (g)), High Risk,Updated CDC Criteria)</title>
          <description>Amendment (f) High Risk Participants updated CDC criteria:&#xD;
Participants received 700 mg BAM +1400 mg ETE + 175 mg BEB administered IV.</description>
        </group>
        <group group_id="E16">
          <title>700 mg BAM 15-min (Addendum (2))</title>
          <description>Participants received 700 mg BAM administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
        </group>
        <group group_id="E17">
          <title>700 mg BAM + 1400 mg ETE 30-min (Addendum (2))</title>
          <description>Participants received 700 mg BAM +1400 mg ETE administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
        </group>
        <group group_id="E18">
          <title>700 mg BAM + 1400 mg ETE 15-min (Addendum (2))</title>
          <description>Participants received 700 mg BAM +1400 mg ETE administered IV.&#xD;
Addendum 2 explored the safety of accelerated intravenous (IV) administration of BAM alone and in combination with ETE.</description>
        </group>
        <group group_id="E19">
          <title>Pooled Placebo (Addendum 4, IV)</title>
          <description>Participants received placebo administered IV.</description>
        </group>
        <group group_id="E20">
          <title>70 mg BEB 140 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 70 mg BEB 140 mg/min IV.</description>
        </group>
        <group group_id="E21">
          <title>175 mg BEB 140 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 175 mg BEB 140 mg/min IV.</description>
        </group>
        <group group_id="E22">
          <title>175 mg BEB 350 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 175 mg BEB 350 mg/min IV.</description>
        </group>
        <group group_id="E23">
          <title>175/700/1400 mg BAM + ETE + BEB 350 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 175 mg BAM + 700 mg ETE + 1400 mg BEB 350 mg/min IV.</description>
        </group>
        <group group_id="E24">
          <title>1750 mg BEB 350 mg/Min (Addendum 4, IV)</title>
          <description>Participants received 1750 mg BEB 350 mg/min IV.</description>
        </group>
        <group group_id="E25">
          <title>Pooled Placebo (Addendum 4, SC)</title>
          <description>Participants received Placebo SC.</description>
        </group>
        <group group_id="E26">
          <title>280 mg BEB (Addendum 4, SC)</title>
          <description>Participants received 280 mg BEB SC.</description>
        </group>
        <group group_id="E27">
          <title>560 mg BEB (Addendum 4, SC)</title>
          <description>Participants received 560 mg BEB SC.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 24.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 24.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="105"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="101"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E11" subjects_affected="15" subjects_at_risk="127"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="128"/>
                <counts group_id="E13" subjects_affected="19" subjects_at_risk="100"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E15" subjects_affected="20" subjects_at_risk="176"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E24" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E25" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E26" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E27" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gingival discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lip blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Covid-19</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Product administration interrupted</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood oestrogen decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fibrin d dimer increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Serum ferritin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin's cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Heavy menstrual bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Intermenstrual bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Spontaneous penile erection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Piloerection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="3" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E24" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E25" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E26" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E27" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

